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Abstract  51 
Context: Use of electronic cigarettes (ECs) is on the rise in most high income countries. 52 
Smoking conventional cigarettes is a known risk factor for urological malignancy incidence, 53 
progression and mortality as well as for other urological health indicators. The potential 54 
impact of EC use on urological health is therefore of clinical interest to the urology 55 
community.    56 
Objective: To review the available data on current EC use including potential benefits in 57 
urological patients, potential issues linked to toxicology of EC constituents and how this 58 
might translate into urological health risks.  59 
Evidence Acquisition: A Medline search was carried out in August 2016 for studies reporting 60 
urological health outcomes and EC use. Snowballing techniques were also used to identify 61 
relevant studies from recent systematic reviews.  A narrative synthesis of data around EC 62 
health outcomes, toxicology, potential use in smoking cessation and health policy was 63 
carried out. 64 
Evidence synthesis: We found no studies to date that have been specifically designed to 65 
assess prospectively urological health risks, even in an observational setting. Generating 66 
such data would be an important contribution to the debate on the role of ECs in public 67 
health and clinical practice. There is evidence from a recent Cochrane review of RCTs that 68 
ECs can support smoking cessation. There are emerging data around potentially harmful 69 
components of ECs such as tobacco-specific nitrosamines, polyaromatic hydrocarbons and 70 
heavy metals could be linked to possible urological health risks.  71 
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Conclusions: ECs might be a useful tool to encourage conventional cigarette smoking 72 
cessation. However, data collection around EC specific impact on urological health is needed 73 
to clarify the possible patient benefit, outcomes and adverse events.  74 
Patient summary: Whilst ECs might help some people to stop smoking, their overall impact 75 
on urological health is not clear.  76 
 77 
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1. Introduction 99 
Tobacco smoking is an established cause of bladder and kidney cancer (50% and 20% of 100 
incident cases, respectively [1]). For people who smoke, there are clear benefits of quitting.  101 
For people who don’t smoke, or would never have started smoking in the absence of EC, 102 
there are potential risks.  As such, it is important for urologists and urological health 103 
researchers to understand the possible implications of EC use in urology patients.[2] 104 
 105 
1.1 What are e-cigarettes?  106 
Electronic cigarettes (ECs) are battery-powered devices that all work by heating a liquid (‘e-107 
liquid’) to create an aerosol that is then inhaled.  The aerosol produced is more commonly 108 
referred to as vapour, and the use of the device as 'vaping'. Some are designed to resemble 109 
traditional cigarettes ('cigalikes' or first generation products), whereas newer generation 110 
(tank systems) are modular and can be personalised. The cigalike devices are closed systems 111 
and are, generally, not refillable. They may be made for single use (i.e. disposable) or they 112 
can have a rechargeable battery and replaceable cartridges that contain the heating coil (or 113 
atomizer) and liquid. The newer generation products are generally greater in size and 114 
consist of a high capacity lithium battery, sometimes with variable power, an atomizer, and 115 
a tank that the user fills with liquid. The atomizer is usually manually activated, which gives 116 
greater control over vapour production than the automated systems. Most people start out 117 
using a cigalike device, but regular vapers generally use tank system ECs [3]. 118 
 119 
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There are three main components of the e-liquid; propylene glycol or glycerol or a mix of 120 
these, nicotine, and flavouring. The propylene glycol/glycerol mix is important for user 121 
satisfaction (e.g. a high propylene glycol content gives a greater ‘throat hit’), but may also 122 
be important for nicotine delivery.[4] Nicotine concentrations vary from 0 to 36mg/ml, with 123 
18mg/ml being the most commonly used.[5, 6] However the European Tobacco Products 124 
Directive, which came into effect on 20 May 2016, now limits the concentration to a 125 
maximum of 20mg/ml. The directive also restricts the volume of bottles of e-liquid to 10ml 126 
and volume of EC tanks to 2ml, as well as a number of other measures including restrictions 127 
on advertising and promotions and packaging and labelling requirements. EC liquid (e-liquid) 128 
is available in numerous flavours, which are important for user satisfaction. In Great Britain, 129 
the most commonly used flavour by current vapers is tobacco, followed by fruit and 130 
mint/menthol flavours.[3] The flavours used are considered safe for oral ingestion, but the 131 
effects of heating these and then inhaling them are unknown. Some flavours appear to be 132 
more cytotoxic than others (e.g. strawberry [7] and cinnamon [8]) and associated with 133 
increased risk of respiratory disease (e.g. diacetyl, [9] which gives a buttery flavour). 134 
 135 
Heating nicotine-containing e-liquid produces nicotine-containing vapour; however, the 136 
association between the concentration of nicotine in the e-liquid and in vapour is 137 
inconsistent. Other factors such as heating of the liquid, voltage and amperage resistance, 138 
and how the user inhales on the EC also have a role to play. ECs also do not deliver as much 139 
nicotine on a puff by puff basis as standard cigarettes.[10] Therefore, vapers typically take 140 
longer puffs than with standard cigarettes (e.g. a mean of 2.4 seconds for conventional 141 
cigarettes versus 4.3 seconds for ECs).[11] 142 
 143 
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1.2. Epidemiology/demographics around EC use 144 
Since being introduced, the prevalence of EC use has seen a relatively rapid increase in 145 
many high-income countries from which national longitudinal data are available, notably 146 
North American and European countries. For example, the prevalence of ever-use among 147 
individuals aged ≥15 years in 27 states of the European Union increased from 7.2% in 2012 148 
to 11.9% in 2014 (Table 1).[12] On average, 15.3% of ever e-cigarette users became current 149 
users in 2014. The greatest increases in the European Union occurred in Malta (5.5% 150 
increase), Ireland (5.1%), Sweden (4.5%), and France (4.3%). In that survey, the lowest 151 
prevalence in 2014 was reported from Portugal (5.7%), whereas the prevalence was 10% or 152 
more in 15 countries, with the highest prevalence in France (21.3%).[12] Experimenting and 153 
ever use of ECs is generally common among youth,[13] but in Europe, prevalence of regular 154 
EC use is much higher in older adults who smoke. In 2014, prevalence of ever EC use in 155 
individuals aged ≥15 years in the United Kingdom was 15.5%, and approximately one 156 
quarter of them transitioned to current users.[12] Among adolescents aged 11–18 years in 157 
Great Britain, prevalence of ever use of ECs in 2014 was 8.2%, while it was 1.7% for monthly 158 
or more use.[14]   159 
 160 
On the other hand, prevalence of more regular use is higher in youth than older adults in 161 
North America. In 2013, 8.5% and 1.8% of Canadians reported ever and current (past 30-162 
day) use of ECs, respectively.[15] The highest prevalence of current use was in age 20–24 163 
(3.9%), followed by age 15–19 (2.6%).[15] In the United States, the prevalence of current 164 
use among individuals aged ≥18 years in 2013–2014 was 3.3%.[16] However, there has been 165 
a substantial increase in ECs use among high-school students in the United States, with 166 
current use prevalence increasing from 1.5% in 2011 to 16.0% in 2015.[17] The recent US 167 
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Surgeon General's report warned that in 2014, current use of ECs by young adults 18–24 168 
years of age surpassed that of adults 25 years of age and older. The report points to 169 
potentially harmful constituents of ECs: particularly nicotine which can lead to addiction and 170 
can harm the developing adolescent brain.[18] 171 
 172 
Information on EC use at the national level from countries in other regions is limited. In a 173 
survey of Chinese adults (age 15–65 years) in Hong Kong in 2014, the prevalence of ever EC 174 
use was 2.3%.[19] Among individuals aged ≥15 years in New Zealand in 2014, 13.1% had 175 
ever used ECs and only 0.8% were current users. The highest prevalence of current use was 176 
in age 22–44 years (1.2%), followed by age ≥45 (0.7%).[20] Prevalence of ever and current 177 
use of ECs among students aged 13–18 years in South Korea in 2011 was 9.4% and 1.4%, 178 
respectively.[21] Since 2011, questions on ECs use have been added to the Global Adult 179 
Tobacco Survey (GATS), which is a nationally representative household survey of individuals 180 
aged ≥15 years in a number of countries.[22] The prevalence of current EC use in four 181 
countries with available data was 0.3% in Indonesia and 0.8% in Malaysia in 2011 and 0.9% 182 
in Qatar and 1.9% in Greece in 2013.[22] It should be noted that due to rapid changes in 183 
prevalence of EC use in some countries, prevalence of use across countries, especially 184 
among youth, may not be comparable using results of surveys conducted in different years.    185 
 186 
EC use has the potential to help smokers to quit cigarette smoking or reduce smoking 187 
intensity.[23] However, one of the primary concerns of EC use is the maintenance of  188 
tobacco use in current smokers (without any substantial decrease in smoking intensity), re-189 
initiation in former smokers, and in particular, nicotine dependence in adolescents,[24-28] 190 
as EC user adolescents may show a higher intention to smoke traditional cigarettes.[25, 27]  191 
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However, in many countries, the rate of EC use by never-smokers or smoking initiation 192 
following EC use has been relatively low, although there might be some variations across 193 
countries. In a survey conducted in 2014 in the European Union, initiation of tobacco use by 194 
using ECs was reported by 0.8% of participants who had used any tobacco product. Use of 195 
nicotine-containing EC among never smokers was low (1.3%), with 0.09% reporting daily 196 
use.[29] The prevalence of current EC use among never-smokers in 2013 was 0.3% in 197 
Canada [15] and 1.4% in the United States.[26] Among adolescents, EC use at least monthly 198 
was reported by only 0.2% of adolescents aged 11–18 years in Great Britain in 2014.[14] 199 
Among middle and high school students in the United States in 2011–2013, prevalence of 200 
current EC use was 0.3% among never smokers.[24] Prevalence of ever and current use of 201 
ECs only (no other tobacco products) in age 13–18 years in South Korea in 2011 was 1.4% 202 
and 1.1%, respectively.[21] Despite low rates of ECs use among never smoker adolescents, 203 
this group could include a substantial number of children, as generally prevalence of 204 
tobacco smoking in this age group is low. For example, the group of never smoker students 205 
that were current ECs users (0.3% of never smokers) in the United States in 2013 included 206 
263,000 children.[24]   207 
 208 
 209 
2. Evidence acquisition 210 
In order to identify any eligible trials addressing EC use and urological health outcomes, a search of 211 
the electronic databases MEDLINE was carried out from inception to August 2016. MEDLINE search 212 
terms were (e-cigarette or electronic-cigarette) AND (bladder or prostate or kidney or urol*). In 213 
addition to database searches, recent systematic reviews of EC use were hand searched for any 214 
potentially eligible trials. To add context to the any available trials data, evidence around smoking 215 
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cessation, available toxicology data and health policy around EC regulations are presented in this 216 
review. Quality appraisal was done subjectively according to expertise and clinical judgement of the 217 
authors. Given that EC use and urological outcomes is an emerging clinical issue with a fragmentary 218 
evidence base and involves rapidly evolving technologies, a narrative synthesis of these data was 219 
undertaken.[30] 220 
 221 
3. Evidence synthesis 222 
3.1 Current urological health outcomes and trials of EC use  223 
We found no published clinical studies, which are a priori designed to evaluate the impact of 224 
ECs on urological health outcomes. We were able to find only one published protocol for a 225 
prospective observational study that will document hospitalizations and adverse events that 226 
could report urological health outcomes (although not specifically designed to do this).[31]  227 
 228 
3.2 Toxicity data and potential urological health impacts from ECs 229 
ECs were introduced into the US and UK markets in 2007 [32] and so their long-term health 230 
risks are not yet clear. Reducing the use of conventional cigarettes has numerous obvious 231 
health benefits including links to incidence and progression of urological malignancies [33] 232 
and complications after primary treatment for urological cancer.[34] EC operation does not 233 
involve combustion and so no smoke or other harmful combustion products, such as tar and 234 
carbon monoxide, are formed. Reduced excretion of tobacco-specific nitrosamines and 235 
other carcinogens has been found in the urine of vapers compared with smokers. [35, 36] 236 
ECs are thought to be much safer for long-term health by the public than traditional tobacco 237 
cigarettes.[37] It is however, important to recognise that these devices are not entirely 238 
benign. Due to the nature and components of these devices, ECs have a diverse hazard 239 
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profile. Operation of EC at high temperatures can generate relatively high levels of 240 
aldehydes [38, 39], which have carcinogenic potential. However vapers naturally avoid this, 241 
as it creates an unpleasant taste (commonly known as a ‘dry puff’)[39, 40]. A recent 242 
systematic review highlighted adverse events linked between EC use and the respiratory, 243 
gastrointestinal, cardiovascular, neurological and immune system; serious leg burns due to 244 
exposure of the battery; serious oral burns, lacerations and fractures from an account of an 245 
EC 'explosion'; both accidental and intentional nicotine overdoses (suicide attempts).[41] 246 
 247 
Data regarding the constituents of ECs is evolving in the literature. Levels of each 248 
component can be varied (e.g. Allen et al (2016) describe over 7000 flavours[42]) and there 249 
is heterogeneity amongst manufacturers.[43] For example, nicotine levels were seen to vary 250 
from 0 mg/ml to 87 mg/ml across studies, and there were reported deviations from the 251 
device label of ingredients of up to 100%.[43] Furthermore, there is inconsistency in the 252 
delivery of chemicals within each puff from the same device or brand. This may be due to 253 
subtle differences in the size of particulate matter within each refill solution and the 254 
delivery system that is used.  255 
 256 
A recent review describes chemical profiles of EC solutions, cartridges, aerosols and 257 
environmental emissions.[43] Whilst ECs are designed to be devoid of tar, some ECs have 258 
been found to contain carcinogens such as tobacco-specific nitrosamines and formaldehyde. 259 
Other constituents such as polyaromatic hydrocarbons and heavy metals are known to 260 
cause cancer, and nicotine itself is thought by some to pose a urological cancer risk. [44, 45] 261 
For instance, polycyclic aromatic hydrocarbons (International Agency for Research on 262 
Cancer (IARC), Group 1 (human carcinogen)[46]), which has been associated with bladder 263 
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cancer.[47] EC have also been found to contain certain heavy metals, such as lead.[48]  Lead 264 
exposure has been linked to increased kidney cancer risk. [49, 50] The concentration of lead 265 
in EC aerosol is variable but has been suggested in at least one analysis to be comparable to 266 
that found in conventional cigarettes.[51] Other heavy metals in EC such as cadmium, nickel 267 
and chromium are possible carcinogens (IARC 2b). Nickel, in particular, has been recorded at 268 
levels present in ECs that are much higher than conventional cigarettes. [51] Although these 269 
heavy metals are linked to an increase cancer risk, they have not yet been linked to 270 
urological malignancies.[49] Cresol, which has been found in aerosols from EC cartridges  is 271 
also found in creosote, a suspect bladder carcinogen.[47]  272 
 273 
In addition, in vitro data has demonstrated that EC vapour exposure, independent of 274 
nicotine content induces increased cell death. In both normal epithelial cells and cancer cell 275 
lines (head and neck squamous cell carcinoma) treated with nicotine free and nicotine-276 
containing vapour, up to a threefold increase in DNA double strand breaks has been 277 
reported.[52] Nicotine is also negatively correlated with total sperm motility due to 278 
metabolic breakdown products cotinine and trans-3’-hydroxycotinine levels in seminal 279 
fluid.[53] Furthermore, cadmium (found in ECs) is associated with low sperm density.[54]  280 
Preliminary evidence from a murine model has reported exposure to EC refill liquid can alter 281 
anti-oxidant defence and induce histopathological changes reflecting renal collecting duct 282 
cell apoptosis.[55]  283 
 284 
Whilst there is a theoretic potential for adverse urological health outcomes from the use of 285 
ECs it should be stressed that robust data are currently absent to offer a convincing 286 
argument for either side of the debate. A recent systematic review of the health 287 
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consequences of vaping/ECs highlighted frequent methodological problems with available 288 
studies, problematic authorship conflicts of interest, small cohort size, selection bias, 289 
conflicting results and a paucity of long-term follow-up data.[48] 290 
 291 
3.3 Can ECs help stop tobacco smoking? 292 
The literature on the role ECs play in smoking cessation is growing very slowly, and the 293 
messages are somewhat mixed. This section summarizes the current evidence from a range 294 
of different study designs and levels of evidence.  295 
 296 
 297 
3.3.1 Prospective cohort studies 298 
Five studies, with long-term outcomes, have looked at the use of ECs in people who were 299 
not ready to quit smoking. One followed 40 smokers over two years and reported that 13% 300 
achieved at least six months of CO validated abstinence from conventional cigarettes and 301 
28% had achieved a sustained ≥50% reduction from baseline cigarette consumption.[56, 57] 302 
The second tested the same approach with 14 smokers with schizophrenia and reported 303 
14% 30-day CO validated abstinence rates at one-year.[58] The third followed a group of 34 304 
smokers for 8 months after discharge from hospital.[59] Over half (53%) reported no longer 305 
smoking. In the fourth, 50 smokers were provided with a second-generation device with 306 
9mg/ml concentration of e-liquid. At 6 month follow-up 36% were biochemically validated 307 
7-day point prevalence abstainers.[60] The fifth cohort study followed 71 smokers who 308 
purchased an EC from a vape shop. One year after their purchase 41% reported that they 309 
had not smoked at all for at least the last 30 days.[61] 310 
 14 
 
 311 
Data are now being reported by the UK stop smoking services. A London-based stop 312 
smoking service offered 100 clients, all of whom wanted to quit smoking, a choice of a first 313 
or second generation EC.[62] In total, 67 accepted the offer and of these 45 (65%) were 314 
recorded as biochemically validated abstainers at the end of treatment (4-weeks post-quit 315 
date). The results from this study closely reflect the UK Stop Smoking Service monitoring 316 
data from over 450,000 people that made a quit attempt, where 4-week self-reported quit 317 
rates were 66% among people who used ECs (n=2221), compared to 48% among people 318 
who used combination NRT (n=135,719).  319 
 320 
Although there are data to support ECs as a potential aid to smoking cessation in the 321 
general population, it is important to note that in those already diagnosed with cancer, 322 
there is less certainty. Prospective cohort data from a major US cancer treatment centre 323 
reported that significantly higher percentage of EC users were highly nicotine dependent 324 
when compared with nonusers and were twice as likely to be smoking at the time of follow-325 
up as nonusers.[63]  326 
 327 
3.3.2 Randomised controlled trials 328 
To date only three randomised controlled trials that have examined the effects of EC in 329 
helping people stop smoking have been published. One examined their use in people who 330 
wanted to quit,[64] and two in those who did not.[65, 66] In a study of people who wanted 331 
to quit from New Zealand [64], the investigators compared nicotine-containing ECs (n=289), 332 
with 21mg nicotine patches (n=295), and with non-nicotine ECs (placebo ECs, n=73). 333 
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Participants were provided with a referral to telephone quitline but with no face-to-face 334 
contact. In this minimal support context, there were no significant differences in validated 335 
continuous abstinence at six months (7.3% nicotine EC, 5.8% nicotine patch, and 4.1% non-336 
nicotine EC). These findings were similar to an Italian study comparing EC use (two different 337 
doses for 12 weeks) to non-nicotine ECs in 300 smokers who were not intending to quit. [65]  338 
Biochemically validated six-month abstinence rates (at one-year follow-up) were not 339 
significantly different; 13%, 9% and 4% in the three groups, respectively. Both of these 340 
pioneering trials were underpowered and used first generation EC products with poor 341 
nicotine delivery. These ECs often malfunctioned and neither is now available on the 342 
market. 343 
 344 
The third trial [66], from Belgium, randomised 48 smokers who did not want to quit to use 345 
an EC (a tank system) or no intervention. At 8-week follow-up, 34% of those given an EC to 346 
use had quit smoking compared to none in control group. From week 8, all participants 347 
were provided with an EC and followed up at 8 months. Among this cohort 19% of early EC 348 
users and 25% of the late starters (the control group) had stopped smoking. The results 349 
from this study are difficult to interpret because of the small sample size and design.   350 
 351 
3.3.3 Systematic reviews 352 
There are now 16 published systematic reviews on ECs for smoking cessation. A recently 353 
updated Cochrane review found that ECs with nicotine helped smokers quit for at least 6 354 
months compared with no nicotine ECs (RR= 2.29, 95% CI: 1.05-4.96; 9% vs. 4%). [67] The 355 
authors of the review gave these findings a ‘low’ confidence rating using GRADE standards, 356 
not because of poor quality studies, but because there are only two studies. Crucially, the 357 
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'low' judgement also means that further research is very likely to have an important impact 358 
on our confidence in the estimate of effect and is likely to change the estimate. The addition 359 
of more trials to this review will further strengthen the conclusions made. Other systematic 360 
reviews draw similar conclusions to the Cochrane review (e.g.[68, 69]), unsurprisingly 361 
because they include the same studies. The review and meta-analysis by Kalkohern and 362 
Glantz [70] came to the opposite conclusion (that EC use is associated with significantly 363 
lower odds of achieving abstinence; OR 0.72; 95% CI: 0.57-0.91). The data in this review 364 
included reports of many small surveys and cohort studies (all with serious limitations) 365 
rendering the findings of this meta-analysis difficult to interpret.  366 
 367 
Given that ECs now deliver nicotine to the user in similar quantities as NRT and even 368 
cigarettes, there is little reason to doubt they could help people stop smoking. Some 369 
estimates of the numbers who have stopped using ECs have been made. For example, 370 
Farsalinos estimated 6.1 million European ever EC users have stopped smoking.[71] In 371 
England this figure is thought to be around 0.56 million. Further research and monitoring 372 
will strengthen confidence in these findings.[72] 373 
 374 
 375 
3.4 European health policy and ECs  376 
The use of ECs for smoking reduction or cessation is influenced by a range of factors that 377 
extend beyond the safety and efficacy of these devices. Regulation also affects their use, in 378 
particular policies that may result in changes to the price, availability or promotion of the 379 
products.[73] The global context for EC regulation is highly variable.[74] In many countries 380 
such as Argentina, Brazil, Indonesia, and Singapore, the import, distribution and sale of ECs 381 
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is banned. Other countries such as New Zealand, South Africa and Switzerland have 382 
implemented a two tier system where ECs themselves and nicotine-free cartridges or e-383 
liquid can be sold sale of but nicotine-containing refills or e-liquid are prohibited. Other 384 
countries permit their import and sale but certain restrictions on age of sale or marketing 385 
are in place. Policies have evolved as use has become more prevalent and governments 386 
have responded to a range of concerns often about youth uptake, addictiveness or safety. 387 
Ironically, many jurisdictions now have more restrictive regulation on ECs than tobacco 388 
products. 389 
In the European Union (EU), EC use is prevalent and countries have taken a range of 390 
approaches to regulation.[29]  From May 2016 the revised EU Tobacco Products Directive 391 
(TPD)  was implemented and article 20 of the Directive applies to ECs and refill containers 392 
that do not have a medicinal license.[75] Only one device, E-Voke (manufactured by British 393 
American Tobacco) has been granted a medicinal license but is not yet available on 394 
prescription or as an over the counter medication.[76] The EU TPD requires manufacturers 395 
and importers of ECs to comply with a notification process that involves providing data on: 396 
ingredients and emissions; nicotine delivery and uptake; health and addictive effects; the 397 
product components and production process; and a declaration on safety and quality when 398 
used as intended. It is anticipated that this process will remove some products from the 399 
market that can’t meet these requirements.  400 
 401 
The TPD also places a limit on nicotine concentration with devices that do not have a 402 
medicinal license limited to 20mg/ml and refill containers up to a maximum volume of 10ml. 403 
The basis for this requirement is contested and some concerns have been expressed about 404 
this limit in terms of delivering nicotine to smokers who are highly dependent.[77] ECs must 405 
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also be secure in terms of leakage and breakage, be child and tamper proof and contain a 406 
leaflet with warnings, instructions and further information. Packaging must contain a 407 
warning label about nicotine being a highly addictive substance and promotional elements 408 
on packaging are also subject to regulation. Some forms of marketing are also restricted 409 
under the TPD including the prohibition of all cross border advertising and sponsorship 410 
although other forms of marketing such as billboards and point of sale are at the discretion 411 
of member states. Finally, annual submissions on products are required to be submitted to 412 
governments and a system for collecting information on adverse effects on health must be 413 
in place. Other policy issues such as age of sale, use in public places and the regulation of 414 
flavours are the responsibility of national governments. 415 
 416 
4. Discussion  417 
We were not able to find any clinical studies with prospective outcomes assessing EC use 418 
and urological outcomes. We have presented data around toxicology of compounds found 419 
in EC constituents and how this might impact urological health, but these must be viewed as 420 
hypothesis generating and treated with caution. As such the use and potential outcomes 421 
associated with EC use in urological patient populations is still to be determined. Some 422 
international studies, such as the International Tobacco Control Survey,[78] are already 423 
providing useful data allowing comparisons of the prevalence of EC use in adults and young 424 
people, impact on smoking cessation, and harm perceptions to be examined across 425 
countries. In the UK, Cancer Research UK and Public Health England have established the UK 426 
Electronic Cigarette Research forum (UKECRF) which brings together researchers from a 427 
range of disciplines three times a year to build new collaborations and pursue studies that 428 
aim to address research gaps. The forum also produces a monthly evidence bulletin 429 
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summarising new studies. Networks of this type are needed in other countries to develop 430 
high quality proposals for EC research and generate evidence to inform policy and practice 431 
in this rapidly developing field. More research on patterns of tobacco use after e-cigarettes 432 
use, in particular among youth, is needed.[79] Also, little information is available on 433 
prevalence of use of nicotine-containing and non-nicotine e-cigarettes. Appropriate 434 
regulations are needed to protect non-smokers especially adolescents, whilst granting 435 
access to smokers to support cessation. In terms of urological health outcomes specifically, 436 
data around vapour emission quantities and compositions would be helpful and to work 437 
towards validated and standardised contents of ECs. This is an important public health 438 
question because EC have been popularised as an aid to smoking cessation, particularly 439 
among teenagers. Given the long latency of most cancers, it may take at least 15 years of 440 
follow up to identify urological cancer risk among EC users. Analysis of the urine of EC users 441 
for compounds such as nitrosamines, aldehydes, lead, arsenic, nickel, chromium and how 442 
these are associated with the development of urological malignancies over time would also 443 
be a valuable addition to the knowledge base. There is also the challenge of differentiating 444 
between conventional cigarette and EC induced health problems, given that most EC users 445 
also smoke conventional cigarettes. In this regard, methodologically robust prospective 446 
studies looking at urological malignancies in EC users would be valuable data to add to this 447 
debate. 448 
 449 
Figure Legends: 450 
Table 1: Selected representative prevalences of e-cigarette use 451 
 452 
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 477 
Table 1.  478 
  Prevalence   
Reference; country, 
year 
Age, no. of 
participants 
E-cigarette use Overall, % Never tobacco 
smokers, % 
Filippidis et al. [12];* 
European Union (27 
countries), 2012–
2014 
≥15 years 
2012: 26,751 
2014: 26,792 
Ever use, 2012  
Ever use, 2014  
Transition of ever to 
current users  
7.2 
11.9 
15.3 (F 14.2; M 17.7) 
 
Eastwood et al. [14]; 
Great Britain, 2013–
2014 
11–18 years 
2013: 2,062 
2014: 1,952 
< monthly, 2013 
Monthly or more, 2013 
< monthly, 2014  
Monthly or more, 2014 
3.7 
0.9 ∫ 
6.5 
1.7 ∫ 
0.6 
0.1 
1.5 
0.2 
Hu et al. [16]; USA, 
2013–2014 
≥18 years 
75,233 
Every or some days 
   All  
   18–24 years 
   25–44 
   45–64 
   ≥ 65 
Every/some days or rarely 
 
3.3 (F 2.8, M 4.0) 
5.5 
4.4 
2.8 
0.9 
6.6 (F 7.9, M 5.5) 
 
Czoli et al. [15]; 
Canada, 2013 
≥15 years 
~2.5 million 
Use in the past 30 days  
   All 
   15–19 years 
   25–44 
   45–64 
   ≥ 45 
 
1.8 (F 1.8, M 1.8) 
2.6 (F 2.1, M 3.0) 
3.9 (F 3.5, M 4.3) 
2.4 (F NR, M 3.0) 
1.0 (F 1.2, M 0.8) 
 
0.5 (F 0.5, M 0.5) 
 
 
 
  Ever use 8.5 (F 8.1, M 8.9) 3.6 (F 3.4, M 3.9) 
Singh et al. [17]; 
USA, 2011–2015 
Middle or high 
school students 
2011: 18,866 
2015: 17,711 
Use in the past 30 days 
   High school, 2015 
   Middle school, 2015 
   High school, 2011 
   Middle school, 2011 
 
16.0 (F 12.8, M 19.0) 
5.3 (F 4.8, M 5.9) 
1.5 
0.6 
 
Jiang et al. [19]; Hong 
Kong, 2014 
15–65 years 
809 
Ever use 
   All 
   15–29 years 
   30–49 
   50–65 
 
2.3 (F 1.3, M 3.6) 
5.2 
1.8 
1.0 
 
1.0 
Li et al. [20]; New 
Zealand, 2014 
≥15 years 
2,594 
Monthly or more 
   All 
   15–17 years 
   18–24 
   25–44 
   ≥ 45 
Ever use 
 
0.8 (F 1.0, M 0.5) 
0.0 
0.2 
1.2 
0.7 
13.1 (F 12.8, M 13.7) 
 
0.1 
Lee et al. [21]; South 
Korea, 2011 
13–18 years 
(students) 
75,643 
Use in the past 30 days 
   All students 
   Grade 7 
   8 
   9 
   10 
   11 
   12 
Ever use 
 
4.7 (F 1.8, M 7.8) 
2.0 
3.3 
4.7 
7.1 
6.0 
6.2 
9.4 
 
0.6 
 
Palipudi et al. [22]; 
Greece, Indonesia, 
≥15 years 
Greece (9,357), 
Current use ** 
Greece 
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  Prevalence   
Reference; country, 
year 
Age, no. of 
participants 
E-cigarette use Overall, % Never tobacco 
smokers, % 
Malaysia, and Qatar, 
2011–2013 
Indonesia 
(8,303), 
Malaysia 
(4,244), Qatar 
(8,389)  
   All  
   15–24 years 
   25–44 
   45–64 
   ≥ 65 
Indonesia 
   All  
   15–24 years 
   25–44 
   45–64 
   ≥ 65 
Malaysia 
   All  
   15–24 years 
   25–44 
   45–64 
   ≥ 65 
Qatar 
   All  
   15–24 years 
   25–44 
   45–64 
   ≥ 65 
1.9 (F 1.8, M 7.8) 
0.0 
2.8 
2.7 
0.8 
 
0.3 (F 1.8, M 7.8) 
0.2 
0.3 
0.3 
0.0 
 
0.8 (F 1.8, M 7.8) 
4.4 
5.0 
0.0 
0.0 
 
0.9 (F 1.8, M 7.8) 
0.5 
1.0 
1.3 
0.0 
1.1 ¶ 
 
 
 
 
 
0.0 ¶ 
 
 
 
 
 
0.1 ¶ 
 
 
 
 
 
0.2 ¶ 
 
Bunnell et al. [24]; 
USA, 2011–2013 
Middle or high 
school students 
61,932 
Use in the past 30 days 
Ever use 
 
6.1 
0.3 
0.9 
F, female; M, male; NR, not-reported.  479 
* Prevalences for individual countries are also presented in the article. 480 
** Those who responded “daily or less than daily” to the question “Do you currently use e-481 
cigarettes on a daily basis, less than daily, or not at all?” 482 
∫ Males were 2.5-times more likely to be monthly or more users than females. 483 
¶ Among those with no current tobacco smoking.  484 
 485 
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